Latest research on Humira

Adalimumab is a human monoclonal antibody against TNF-alpha. It is produced by recombinant DNA technology using a mammalian cell expression system. It consists of 1330 amino acids and has a molecular weight of approximately 148 kilodaltons.

Humira interactions

Biologic agents were mainly in decreasing order of frequency: etanercept (Enbrel), adalimumab (Humira), abatacept (Orencia), rituximab (MabThera), and tocilizumab (Actemra). [source, 2016]
Of these, the most common were Humira with 5 unique ads and Cymbalta and Vyvanse with 3 unique ads each. [source, 2016]
The eligible drug list currently comprises adalimumab (Humira), etanercept (Enbrel) and certolizumab pegol (Cimzia). [source, 2015]
Biologic disease-modifying antirheumatic drugs (bDMARDs), also known as biologics, cover TNF inhibitors (TNFi) (adalimumab (ADA) (Humira, AbbVie Ltd.), certolizumab pegol (CER) (Cimzia, UCB Pharma SA), etanercept (ETN) (Enbrel, Pfizer Ltd.), golimumab (GOL) (Simponi, Janssen Biologics B.V), infliximab (IFX) (Remicade, Janssen Biologics B.V.)) and agents based on other mechanisms of action (abatacept (ABT) (Orencia, Bristol-Myers Squibb Pharma EEIG), anakinra (ANA) (Kineret, Biovitrum AB), rituximab (RTX) (MabThera, Roche Registration Ltd) and tocilizumab (TOC) (RoActemra, Roche Registration Ltd. [source, 2015]
Six DMARDs were used in both Saudis and non-Saudis, with no significant difference between these 2 populations for each DMARD; the most frequently used DMARD was MTX followed by hydroxychloroquine sulphate (Plaquenil), Glucocorticoids (Prednisolone), Adalimumab (Humira), Sulfasalazine and Leflunomide (Arava) ( [source, 2015]
The annual sales of the top-selling antibody drugs, such as Humira, Remicade, Avastin, Rituxan and Herceptin, are over or close to $ 10 billion now while many potential blockbusters are being investigated in clinical trials [1, 2]. [source, 2015]
Five top-selling therapeutic antibodies which are also popular biosimilar candidates for many biotech companies, namely Herceptin (trastuzumab), Avastin (bevacizumab), Remicade (infliximab), Rituxan (rituximab) and Humira (adalimumab), were used as model molecules in this study. [source, 2015]
The optimized signal peptides for Herceptin, Avastin, Remicade, Rituxan and Humira were identified. [source, 2015]
The variable regions and the constant regions of the HC and LC of Herceptin, Avastin, Remicade, Rituxan and Humira were generated based on publicly available information. [source, 2015]
Interestingly, the HC signal peptide 7 (H7) resulted in significantly increased secretion for Avastin, Remicade, Rituxan and Humira. [source, 2015]